Familial Breast Cancer in China

N/ANot Yet RecruitingNCT06833216

Cancer Institute and Hospital, Chinese Academy of Medical Sciences500 enrolled

Overview

This study is a retrospective descriptive study to collect clinical data (mainly including medical records and follow-up information, etc.) of breast cancer patients with genetic variation who were first diagnosed and treated in a number of hospitals in China during the period from January 1, 2015 to December 31, 2024, and to establish a retrospective cohort of familial hereditary breast cancer. To analyze the clinical features, diagnosis and treatment and survival prognosis of patients with familial hereditary breast cancer. To explore the main factors affecting clinical diagnosis and treatment and survival prognosis of patients

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Breast Carcinoma Genetic Variation

Interventions

Genetic variationOTHER

To observe and describe the clinical features, diagnosis and treatment plan and survival prognosis of familial hereditary breast cancer in China, and explore the main factors affecting prognosis.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Familial inherited breast cancer with genetic variants, including but not limited to mutations in the BRCA1, BRCA2, TP53, and PALB2 genes * The patient had no major organ dysfunction * ECOG score 0-1 Exclusion Criteria: * There are serious dysfunction of vital organs (heart, liver, kidney) * Patients with other malignancies, except cured non-melanoma skin cancer, cervical carcinoma in situ and other tumors that have been cured for at least 5 years * In other acute infectious disease or chronic infectious disease activity period * A history of uncontrolled seizures, central nervous system disorders, or mental disorders

Familial Breast Cancer in China

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Central Contacts